---
schema_version: "secwatch.filing_event.v1"
accession: "0001051514-22-000091"
form_type: "8-K"
ticker: "SSKN"
cik: "0001051514"
company_name: "STRATA Skin Sciences, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T00:32:51.623640+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# STRATA Q3 2022 revenue $9.4M (+22% YoY); net loss widens; launches TheraClear X

## Summary
- Revenue $9.4M vs $7.7M YoY (+22%); equipment revenue $3.6M (+80%); international sales $3.3M (+82%).
- Net loss $1.0M ($0.03/sh) vs $0.5M loss ($0.02/sh) in Q3 2021; non-GAAP adjusted EBITDA $1.1M up from $0.9M.
- Gross margin 61.6% (GAAP) vs 69.7% YoY; non-GAAP gross margin 67.0% vs 71.6%, impacted by amortization and product mix.
- U.S. commercial launch of TheraClear X acne therapy system targeting a $5.5B acne treatment market.
- Reiterates FY2022 revenue guidance of $33M–$35M, expects strong double-digit year-over-year growth.

## SEC filing metadata
- accession: 0001051514-22-000091
- form_type: 8-K
- ticker: SSKN
- cik: 0001051514
- company_name: STRATA Skin Sciences, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1051514/000105151422000091/0001051514-22-000091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1051514/000105151422000091/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001051514-22-000091
- JSON: https://secwatch.observer/filing/0001051514-22-000091.json
- Plain text: https://secwatch.observer/filing/0001051514-22-000091.txt

## Key facts
- Earnings Releases
  STRATA Skin Sciences, Inc. reported full-year 2022 results: revenue $33 million to $35 million. Guidance reaffirmed.
  - Period: full-year 2022
  - Revenue: $33 million to $35 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: The company reiterated its full-year 2022 revenue guidance in the range of $33 million to $35 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1051514/000105151422000091/0001051514-22-000091-index.htm
- Earnings Releases
  STRATA Skin Sciences, Inc. reported third quarter ended September 30, 2022 results: net income $1.0 million, EPS $0.03. Guidance reaffirmed.
  - Period: third quarter ended September 30, 2022
  - Net income: $1.0 million
  - EPS: $0.03
  - Guidance: reaffirmed
  - Result: reported results
  source text: STRATA Skin Sciences Reports Strong Third Quarter 2022 Financial Results ● Strong revenue in the third quarter 2022 of $9.4 million , a 22% increase over the third quarter of 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1051514/000105151422000091/0001051514-22-000091-index.htm
- Earnings Releases
  STRATA Skin Sciences, Inc. reported third quarter ended September 30, 2022 results: net income $1.0 million, EPS $0.03. Guidance reaffirmed.
  - Period: third quarter ended September 30, 2022
  - Net income: $1.0 million
  - EPS: $0.03
  - Guidance: reaffirmed
  - Result: reported results
  source text: Revenues for the third quarter of 2022 were $9.4 million, as compared to revenues of $7.7 million for the third quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1051514/000105151422000091/0001051514-22-000091-index.htm
- Earnings Releases
  STRATA Skin Sciences, Inc. reported third quarter ended September 30, 2022 results: net income $1.0 million, EPS $0.03. Guidance reaffirmed.
  - Period: third quarter ended September 30, 2022
  - Net income: $1.0 million
  - EPS: $0.03
  - Guidance: reaffirmed
  - Result: reported results
  source text: Net loss for third quarter 2022 was $1.0 million, or a loss of $0.03 per basic and diluted common share, as compared to the net loss for the third quarter of 2021 of $0.5 million, or net loss of $0.02 per basic and diluted common share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1051514/000105151422000091/0001051514-22-000091-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.